Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma

Inclusion Criteria: * Give written informed consent prior to study, with understanding that the patient has the right to withdraw from the study at any time without prejudice * Be female of male and ≥18 and ≤75 years of age * Be ambulatory and have ECOG performance status of ≤1 * Have histological confirmed sarcoma * Locally advanced or metastatic sarcoma who receive first-line chemotherapy. * Have at least one target lesion according to the RECIST criteria. Exclusion Criteria: * Pregnant or lactating women * patient has received chemotherapy drugs including gemcitabine,vincristine and cisplatin * Chemotherapy within four weeks preceding treatment start * ECOG ≥ 2 * Radiotherapy to the axial skeleton within the 4 weeks preceding study treatment start or insufficient recovery from the effects of prior radiotherapy * Participation in any investigational drug study within 4 weeks preceding treatment start * History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix .Abnormal laboratory values: hemoglobin \< 8. 0g/dl, neutrophil\< 1.5×109/L, platelet\< 100×109/L. * serum creatine \> upper limit of normal (ULN) * serum bilirubin \> ULN * alanine aminotransferase(ALT) and aspartate aminotransferase(AST)\>5×ULN * alkaline phosphatase(AKP)\>5×ULN * Serious uncontrolled intercurrence infection * Life expectancy of less than 3 months